Musashi2在不同分子分型乳腺浸润性导管癌中的表达及临床意义  

Expression and its clinical significance of Musashi2 in different molecular subtypes of breast invasive ductal carcinoma

作　　者：平静[1] 周东华[1] 朱大江[2] 田杰[1] 陈莹[1] 范菊花[1] PING Jing;ZHOU Donghua;ZHU Dajiang;TIAN Jie;CHEN Ying;FAN Juhua(Department of Pathology,Foshan Women and Children Hospital,Foshan 528000,China;Breast Disease Prevention and Control Center,Foshan Women and Children Hospital,Foshan 528000,China)

机构地区：[1]佛山市妇幼保健院病理科,528000 [2]佛山市妇幼保健院乳腺疾病防治中心,528000

出　　处：《天津医药》2022年第9期907-911,共5页Tianjin Medical Journal

基　　金：广东省医学科研基金资助项目(A2019172)。

摘　　要：目的探讨Musashi2在不同分子分型乳腺浸润性导管癌中的表达及其与临床和分子病理特征及预后的相关性。方法收集125例乳腺浸润性导管癌患者的临床病理资料,采用免疫组织化学法检测肿瘤组织Musashi2、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(HER2)和Ki67表达,对HER2检测结果为“++”的病例进一步做荧光原位杂交(FISH)检测,依据检测结果进行分子分型,分析Musashi2表达与不同分子分型乳腺浸润性导管癌临床和分子病理特征及预后的关系。结果Musashi2在乳腺浸润性导管癌和导管原位癌中的阳性率明显高于正常乳腺组织(P<0.01)。在Luminal A型和Luminal B型中的阳性率明显高于HER2过表达型和三阴型(P<0.01)。在TNM分期的早期(Ⅰ+Ⅱ期)患者的阳性率明显高于晚期(Ⅲ+Ⅳ期)患者(P<0.05),但在不同年龄、肿瘤直径、组织学分级,脉管是否受累和淋巴结有无转移的乳腺润性导管癌,Musashi2的表达差异无统计学意义(P>0.05)。Musashi2表达水平与ER、PR呈显著正相关(r分别为0.408和0.405,P<0.05),与HER2和Ki67无关(P>0.05)。Kaplan-Meier生存分析表明Musashi2阳性组和阴性组术后无病生存时间差异无统计学意义[(67±12)个月vs.(63±15)个月,Log-rankχ^(2)=0.752,P>0.05]。结论Musashi2蛋白在乳腺浸润性导管癌组织中的表达与其分子分型和TNM分期有关,Musashi2高表达提示肿瘤恶性程度较低。Objective To investigate the expression of Musashi2 in different molecular subtypes of breast invasive ductal carcinoma and its correlation with clinical and molecular pathological features and prognosis.Methods The clinicopathological data of 125 patients with breast invasive ductal carcinoma were collected.The expression of Musashi2,estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor-2(HER2)and Ki67 expression in tumor tissues were detected by immunohistochemistry.Fluorescence in situ hybridization(FISH)was further detected in patients with a"++"HER2 immunohistochemistry results.According to the test results,molecular subtyping was performed.The relationship between Musashi2 expression and its clinical and molecular pathological characteristics and prognosis was analyzed in breast invasive ductal carcinoma with different molecular subtypes.Results The positive rates of Musashi2 in invasive ductal carcinoma and ductal carcinoma in situ were significantly higher than those in normal breast tissues(P<0.01).The positive rates in the Luminal A and the Luminal B groups were significantly higher than that in the HER2+and triple-negative type groups(P<0.05).The positive rates of Musashi2 in early stage(ⅠandⅡ)were significantly higher than those in the late stage(ⅢandⅣ,P<0.05).However,there were no significant differences in Musashi2 expression levels between different ages,tumor diameters,histological grades,vascular involvement and lymph node metastasis of invasive ductal carcinoma of breast(P>0.05).The expression level of Musashi2 was positively correlated with ER and PR(r=0.408,r=0.405),but no relationship with HER2 and Ki67(P>0.05).Kaplan-Meier survival analysis showed that there was no significant difference in disease-free survival between the Musashi2 positive group and the Musashi2 negtive group(67 months±12 months vs.63 months±15 months,Log-rankχ^(2)=0.752,P>0.05).Conclusion The expression of Musashi2 protein in breast invasive ductal carcinoma is related to its mo

关 键 词：乳腺肿瘤 癌 导管 乳腺 病理学 临床 Musashi2 

分 类 号：R737.9[医药卫生—肿瘤]